JPRN-jRCT2011200018进行中（未招募）2 期
ONO-7702/7703-03:A Phase 2 study of Combination of ONO-7702 and ONO-7703 in Patients with Radically Unresectable BRAF V600-mutant Thyroid Cancer
Hirashima Yoshinori0 个研究点目标入组 19 人开始时间: 2021年1月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Age >= 20 years
- •2. histologically diagnosed radically unresectable locally advanced or distant metastatic thyroid cancerars
- •3. positive BRAF V600 mutation
- •4. ECOG Performance Status of 0 or 1
- •5. Able to swallow, ingest, and absorb oral drugs
排除标准
- •1. Prior treatment with any RAF inhibitor or MEK inhibitor
- •2. symptomatic brain metastasis, leptomeningeal disease, or other active central nervous system (CNS) metastasis
研究者
相似试验
已完成
2 期
A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer.10027656Breast cancerNL-OMON35692ovartis5
进行中（未招募）
1 期
A clinical study investigating the combination of RAD001 with trastuzumaband paclitaxel in patients with breast cancermetastatic breast cancerEUCTR2006-001596-37-BEovartis Pharma Services AG55
进行中（未招募）
1 期
The effect of anti-latency reversing therapy and broadly neutralizing antibodies on the HIV-1 reservoir in patients on antiretroviral therapy - a randomized trial (ROADMAP)HIV infectionMedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848MedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-005238-23-DKRockefeller University30
进行中（未招募）
1 期
A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP).EUCTR2015-005238-23-DEThe Rockefeller University30
进行中（未招募）
2 期
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)carcinoma, ovarian epithelialD000077216JPRN-jRCT2031190097Fujiwara Keiichi24